Published in Gastroenterology on June 01, 2013
Advantages of fluorescence-guided laparoscopic surgery of pancreatic cancer labeled with fluorescent anti-carcinoembryonic antigen antibodies in an orthotopic mouse model. J Am Coll Surg (2014) 3.12
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun (2015) 1.94
Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun (2015) 1.33
A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clin Cancer Res (2014) 1.10
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget (2014) 1.10
Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget (2015) 1.08
Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice. Gastroenterology (2014) 0.99
Celiac plexus neurolysis in pancreatic cancer: the endoscopic ultrasound approach. World J Gastroenterol (2014) 0.98
Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. J Gastroenterol (2014) 0.97
Pancreatic cancer and its stroma: a conspiracy theory. World J Gastroenterol (2014) 0.94
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 0.91
Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res (2014) 0.90
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma. Oncotarget (2015) 0.89
PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradation of β-catenin. Oncol Rep (2014) 0.89
Pancreatic cancer diagnosis by free and exosomal miRNA. World J Gastrointest Pathophysiol (2013) 0.89
Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol (2015) 0.89
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol (2015) 0.87
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology (2015) 0.86
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res (2015) 0.86
The pseudokinase SgK223 promotes invasion of pancreatic ductal epithelial cells through JAK1/Stat3 signaling. Mol Cancer (2015) 0.85
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Surg Today (2016) 0.84
Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Clin Cancer Res (2014) 0.84
When to puncture, when not to puncture: Pancreatic masses. Endosc Ultrasound (2014) 0.83
Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. Cancer Sci (2015) 0.82
Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. Cancer Res (2014) 0.82
Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer. Cancer Sci (2014) 0.82
Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Langenbecks Arch Surg (2015) 0.81
Targeting miRNAs for pancreatic cancer therapy. Curr Pharm Des (2014) 0.81
Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Sci Rep (2015) 0.81
Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Rep (2016) 0.81
Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models. Oncotarget (2016) 0.81
Mesenchymal stem cells promote pancreatic adenocarcinoma cells invasion by transforming growth factor-β1 induced epithelial-mesenchymal transition. Oncotarget (2016) 0.80
Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling pathway. Oncol Lett (2014) 0.80
Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Autophagy (2016) 0.80
The secret origins and surprising fates of pancreas tumors. Carcinogenesis (2014) 0.80
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget (2015) 0.80
Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Oncotarget (2016) 0.80
Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. J Exp Clin Cancer Res (2015) 0.80
Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival. Pancreas (2015) 0.80
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. BMC Cancer (2014) 0.79
Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget (2016) 0.78
Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. Mol Cancer Ther (2014) 0.78
Analysis of prognostic factors for pancreatic head cancer according to para-aortic lymph node. Cancer Med (2016) 0.77
Magnetic resonance-guided regional gene delivery strategy using a tumor stroma-permeable nanocarrier for pancreatic cancer. Int J Nanomedicine (2015) 0.77
Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. Mol Pharm (2015) 0.77
Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles. Transl Oncol (2015) 0.77
Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr (2014) 0.77
Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer? World J Gastroenterol (2014) 0.76
Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer. Cancer Lett (2015) 0.76
The pancreas: biology, diseases, and therapy. Gastroenterology (2013) 0.76
Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Mol Cell Proteomics (2016) 0.75
Hematogenous Gastric Metastasis of Pancreatic Cancer. Case Rep Gastroenterol (2016) 0.75
Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements. Biomed Res Int (2017) 0.75
Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells. Am J Cancer Res (2016) 0.75
Modified methods for isolation of pancreatic stellate cells from human and rodent pancreas. J Biomed Res (2016) 0.75
Pancreatic ductal adenocarcinoma with inferior vena cava invasion: a report of three resected cases. Surg Case Rep (2017) 0.75
Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Cell Rep (2016) 0.75
Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget (2016) 0.75
Identification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancer. Medicine (Baltimore) (2016) 0.75
Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol (2016) 0.75
Fentanyl inhibits cell viability in human pancreatic cancer cell line and tumor growth in pancreatic cancer cell-transplanted mice. Int J Clin Exp Med (2015) 0.75
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine. Oncotarget (2016) 0.75
Moscatilin induces apoptosis of pancreatic cancer cells via reactive oxygen species and the JNK/SAPK pathway. Mol Med Rep (2017) 0.75
Porcine cancer models for translational oncology. Mol Cell Oncol (2014) 0.75
Distribution and pathological features of pancreatic, ampullary, biliary and duodenal cancers resected with pancreaticoduodenectomy. World J Surg Oncol (2015) 0.75
Epigenetically altered miR-1247 functions as a tumor suppressor in pancreatic cancer. Oncotarget (2017) 0.75
MiR-181b-5p, ETS1 and c-Met pathway exacerbates the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Sci (2017) 0.75
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival. BMC Gastroenterol (2015) 0.75
Tumor-specific gene therapy for pancreatic cancer using human neural stem cells encoding carboxylesterase. Oncotarget (2016) 0.75
mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Oncotarget (2016) 0.75
Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer. Int J Med Sci (2016) 0.75
Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence. World J Surg (2017) 0.75
TGF-β in pancreatic cancer initiation and progression: two sides of the same coin. Cell Biosci (2017) 0.75
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS One (2017) 0.75
A quantitative method for screening and identifying molecular targets for nanomedicine. J Control Release (2017) 0.75
Identification of the serine biosynthesis pathway as a critical component of BRAF inhibitor resistance of melanoma, pancreatic, and non-small cell lung cancer cells. Mol Cancer Ther (2017) 0.75
N1-guanyl-1, 7-diaminoheptane enhances the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine via the inhibition of eukaryotic translation initiation factor 5A2. Exp Ther Med (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med (2011) 4.10
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A (2009) 3.08
Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg (2008) 2.80
Sox17 regulates organ lineage segregation of ventral foregut progenitor cells. Dev Cell (2009) 2.14
Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.11
beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res (2002) 1.86
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol (2005) 1.78
Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology (2005) 1.78
Wnt/beta-catenin signaling is required for development of the exocrine pancreas. BMC Dev Biol (2007) 1.68
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2007) 1.53
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J Am Coll Surg (2005) 1.48
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res (2007) 1.47
Ampullary carcinoid tumors: rationale for an aggressive surgical approach. J Gastrointest Surg (2003) 1.45
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol (2009) 1.38
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol (2013) 1.36
Total pancreatectomy and autologous islet cell transplantation as a means to treat severe chronic pancreatitis. J Gastrointest Surg (2003) 1.35
Duodenal gangliocytic paraganglioma with lymph node metastasis: a case report and review of the literature. Arch Pathol Lab Med (2003) 1.33
Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res (2010) 1.31
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs (2008) 1.30
Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res (2010) 1.27
Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]. Proc Natl Acad Sci U S A (2010) 1.27
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer (2003) 1.26
Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res (2006) 1.24
Knockdown of the β(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int J Cancer (2011) 1.22
KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res (2012) 1.22
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas (2008) 1.15
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol (2010) 1.15
Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm (2010) 1.14
Complementarity of ultrasound and fluorescence imaging in an orthotopic mouse model of pancreatic cancer. BMC Cancer (2009) 1.14
Increased biliary fistulas after liver resection with the harmonic scalpel. Am Surg (2003) 1.13
Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget (2011) 1.09
Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med (2012) 1.06
Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB (Oxford) (2010) 1.04
Adenomatous polyposis coli/beta-catenin interaction and downstream targets: altered gene expression in gastrointestinal tumors. Clin Colorectal Cancer (2003) 1.04
Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol (2004) 1.00
The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol (2014) 1.00
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg (2013) 0.98
Sociodemographic Predictors of Survival in Differentiated Thyroid Cancer: Results from the SEER Database. ISRN Endocrinol (2012) 0.98
Chronic pancreatitis: recent advances and ongoing challenges. Curr Probl Surg (2006) 0.98
Chemokine receptor CXCR4 enhances proliferation in pancreatic cancer cells through AKT and ERK dependent pathways. Pancreas (2010) 0.97
IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. Carcinogenesis (2011) 0.96
The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology (2008) 0.96
In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody. Ann Surg Oncol (2013) 0.96
The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. Int J Cancer (2012) 0.94
PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A (2013) 0.94
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest (2008) 0.94
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol (2014) 0.93
Fistulojejunostomy for the management of refractory pancreatic fistula. Surgery (2007) 0.92
Technology for the delivery of hyperthermic intraoperative intraperitoneal chemotherapy: a survey of techniques. Recent Results Cancer Res (2007) 0.92
Case report: focal nesidioblastosis ("nesidioblastoma") in an adult. Hum Pathol (2009) 0.92
VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol (2007) 0.92
Osteoclast-like giant cell tumor of the pancreas associated with a mucinous cystadenocarcinoma. Surgery (2003) 0.92
Pancreaticoduodenectomy. J Gastrointest Surg (2005) 0.90
Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys (2007) 0.90
The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells. Pancreas (2010) 0.89
CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells. J Gastrointest Surg (2009) 0.89
Long-term outcomes after total pancreatectomy and islet cell autotransplantation: is it a durable operation? Ann Surg (2014) 0.88
Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Surg Oncol Clin N Am (2003) 0.88
Monoclonal antibodies and other targeted therapies for pancreatic cancer. Cancer J (2012) 0.87
Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw (2005) 0.87
Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res (2013) 0.87
An algorithm for the accurate identification of benign liver lesions. Am J Surg (2004) 0.86
Forequarter amputation for recurrent breast cancer: a case report and review of the literature. J Surg Oncol (2005) 0.86
Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol (2006) 0.86
Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. J Transl Med (2014) 0.85
Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2005) 0.85
Clinical significance of bacterial cultures from 28 autologous islet cell transplant solutions. Pancreatology (2005) 0.85
A comparison of pancreaticoduodenectomy and duodenum-preserving head resection for the treatment of chronic pancreatitis. HPB (Oxford) (2009) 0.85
Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer. Pancreas (2013) 0.84
Enhancing magnetic resonance imaging tumor detection with fluorescence intensity and lifetime imaging. J Biomed Opt (2011) 0.84
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol (2012) 0.84
Intraoperative margin re-resection for colorectal liver metastases. J Surg Educ (2007) 0.84
The battle of the sexes: women win out in gastrointestinal surgery. J Surg Res (2011) 0.83
Upregulation of thrombospondin-1 and angiogenesis in an aggressive human pancreatic cancer cell line selected for high metastasis. Mol Cancer Ther (2009) 0.83
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol (2012) 0.82
Systemic therapy for pancreatic cancer. Semin Radiat Oncol (2005) 0.82
Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology (2008) 0.81
HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed (2014) 0.81
The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas (2014) 0.80
Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2014) 0.79
Cerebral edema in a patient following cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemoperfusion. World J Surg Oncol (2006) 0.79
Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy. Ann Surg Oncol (2014) 0.78
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas (2016) 0.78
Uncommon anal neoplasms. Surg Oncol Clin N Am (2004) 0.78
Single-incision laparoscopic surgery through an ostomy site: a natural approach by an unnatural orifice. Surg Laparosc Endosc Percutan Tech (2015) 0.78
Density of surgeons is significantly associated with reduced risk of deaths from motor vehicle crashes in US counties. J Am Coll Surg (2011) 0.77
A dual-color genetically engineered mouse model for multispectral imaging of the pancreatic microenvironment. Pancreas (2013) 0.77
Multiple focal nodular hyperplasia of the liver in a 21-year-old woman. J Gastrointest Surg (2004) 0.77
Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a. J Nucl Med (2002) 0.76
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.76
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol (2016) 0.75
Cystic neoplasms of the pancreas. Surg Oncol Clin N Am (2010) 0.75